Drug Profile
HC SVT 1001
Alternative Names: Adipose-derived-stem-cells-Salvat; Allogeneic-mesenchymal-stem-cells-SalvatLatest Information Update: 23 Mar 2021
Price :
$50
*
At a glance
- Originator SALVAT
- Class Cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pseudoarthrosis
Most Recent Events
- 17 Mar 2021 Salvat completes a phase II trial in Pseudarthrosis in Spain (NCT02483364)
- 11 Jul 2016 HC SVT 1001 is still in phase I/II trial for Pseudarthrosis in Spain (EudraCT2013-000930-37) (NCT02483364)
- 29 Apr 2014 Phase-I/II clinical trials in Pseudoarthrosis in Spain (Intraosseous, Implant) (EudraCT2013-000930-37)